As bankrupt homegrown company Athenex Inc. fades away, where does Western New York go from here in its hunt for a biotech blockbuster? That's unclear, though having a lineup of promising companies in ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min ImmunityBio plans to use the ...

A monumental achievement for ImmunityBio, Inc., occurred earlier this week, leaving the door open for potential major benefits to the Dunkirk community. Earlier this week, the Food and Drug ...

Town of Dunkirk resident Sue Hazelton is never shy to bring something before the Town Board during public comments. At the most recent meeting, her question for the Board was one that many in the ...

ANKTIVA ® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product ImmunityBio’s 400,000 square foot GMP fill-finish facility in ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

Over 400,000 square foot, state-of-the-art, finish-fill and lyophilization facility enables one billion doses of RNA and adjuvant vaccine production Newly constructed Current Good Manufacturing ...

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Friday after the company announced overall survival results in its QUILT 3.055 study. ImmunityBio said the QUILT 3.055 trial shows median ...

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time.

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for “fill finish” (filling vials and ...